Structure-function studies of polymyxin B lipononapeptides

Molecules

Volumn 24, Issue 3, 2019, Pages

  Gallardo Godoy, Alejandra ^a   Hansford, Karl A ^a   Muldoon, Craig ^a   Becker, Bernd ^a   Elliott, Alysha G ^a   Huang, Johnny X ^a   Pelingon, Ruby ^a   Butler, Mark S ^a   Blaskovich, Mark A T ^a   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibiotic resistance; Antibiotics; Lipopeptide; Nonapeptide; Polymyxin

Indexed keywords

ANTIINFECTIVE AGENT; FATTY ACID; PEPTIDE; POLYMYXIN B;

CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; HUMAN; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION;

ANTI-INFECTIVE AGENTS; CELL PROLIFERATION; FATTY ACIDS; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; POLYMYXIN B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85061057939     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules24030553     Document Type: Article

References (45)

1. Benedict, R.G.; Langlykke, A.F. Antibiotic Activity of Bacillus polymyxa. J. Bacteriol. 1947, 54, 24–25. [PubMed]
2. Stansly, P.G.; Schlosser, M.E. Studies on Polymyxin—Isolation and Identification of Bacillus polymyxa and Differentiation of Polymyxin from Certain Known Antibiotics. J. Bacteriol. 1947, 54, 549–556. [PubMed]
3. Stansly, P.G.; Brownlee, G. Nomenclature of Polymyxin Antibiotics. Nature 1949, 163, 611. [CrossRef] [PubMed]
4. Stansly, P.G.; Shepherd, R.G.; White, H.J. Polymyxin—A New Chemotherapeutic Agent. Bull. Johns Hopkins Hosp. 1947, 81, 43–54. [PubMed]
5. Shoji, J.; Kato, T.; Hinoo, H. Structures of 2 New Polymyxin Group Antibiotics. J. Antibiot. 1977, 30, 427–429. [CrossRef] [PubMed]
6. Shoji, J.; Hinoo, H.; Wakisaka, Y.; Koizumi, K.; Mayama, M.; Matsuura, S. Isolation of Two New Polymyxin Group Antibiotics (Studies on Antibiotics from Genus Bacillus. XX). J. Antibiot. 1977, 30, 1029–1034. [CrossRef]
7. Wilkinson, S.; Lowe, L.A. Structures of Polymyxins A and the Question of Identity with the Polymyxins M. Nature 1966, 212, 311. [CrossRef]
8. Parker, W.L.; Rathnum, M.L.; Dean, L.D.; Nimeck, M.W.; Brown, W.E.; Meyers, E. Polymyxin-F, a New Peptide Antibiotic. J. Antibiot. 1977, 30, 767–769. [CrossRef]
9. Zavascki, A.P.; Nation, R.L. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Antimicrob. Agents Chemother. 2017, 61. [CrossRef]
10. Manchandani, P.; Zhou, J.; Babic, J.T.; Ledesma, K.R.; Truong, L.D.; Tam, V.H. Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. Antimicrob. Agents Chemother. 2017, 61. [CrossRef]
11. Codjoe, F.S.; Donkor, E.S. Carbapenem Resistance: A Review. Med. Sci. 2017, 6, 1. [CrossRef] [PubMed]
12. Van Loon, K.; Voor In’t Holt, A.F.; Vos, M.C. A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 2018, 62. [CrossRef] [PubMed]
13. Bush, K. Past and Present Perspectives on β-Lactamases. Antimicrob. Agents Chemother. 2018, 62. [CrossRef] [PubMed]
14. Bush, K. Proliferation and significance of clinically relevant β-lactamases. Ann. NY Acad. Sci. 2013, 1277, 84–90. [CrossRef] [PubMed]
15. PEW. A Scientific Roadmap for Antibiotic Discovery. 2016. Available online: http://www.pewtrusts.org/~{}/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf (accessed on 31 January 2019).
16. Luepke, K.H.; Suda, K.J.; Boucher, H.; Russo, R.L.; Bonney, M.W.; Hunt, T.D.; Mohr, J.F. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy 2017, 37, 71–84. [CrossRef] [PubMed]
17. Butler, M.S.; Blaskovich, M.A.T.; Cooper, M.A. Antibiotics in the clinical pipeline at the end of 2015. J. Antibiot. 2017, 70, 3–24. [CrossRef] [PubMed]
18. Tran, T.B.; Velkov, T.; Nation, R.L.; Forrest, A.; Tsuji, B.T.; Bergen, P.J.; Li, J. Pharmacokinetics/ pharmacodynamics of colistin and polymyxin B: Are we there yet? Int. J. Antimicrob. Agent 2016, 48, 592–597. [CrossRef] [PubMed]
19. Nation, R.L.; Li, J.; Cars, O.; Couet, W.; Dudley, M.N.; Kaye, K.S.; Mouton, J.W.; Paterson, D.L.; Tam, V.H.; Theuretzbacher, U.; et al. Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus. Lancet Infect. Dis. 2015, 15, 225–234. [CrossRef]
20. Roberts, K.D.; Azad, M.A.K.; Wang, J.P.; Horne, A.S.; Thompson, P.E.; Nation, R.L.; Velkov, T.; Li, J. Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-Line Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. ACS Infect. Dis. 2015, 1, 568–575. [CrossRef]
21. Rabanal, F.; Cajal, Y. Recent advances and perspectives in the design and development of polymyxins. Nat. Prod. Rep. 2017, 34, 886–908. [CrossRef]
22. Baron, S.; Hadjadj, L.; Rolain, J.M.; Olaitan, A.O. Molecular mechanisms of polymyxin resistance: Knowns and unknowns. Int. J. Antimicrob. Ag. 2016, 48, 583–591. [CrossRef] [PubMed]
23. Hancock, R.E.W.; Chapple, D.S. Peptide antibiotics. Antimicrob. Agents Chemother. 1999, 43, 1317–1323. [CrossRef] [PubMed]
24. Velkov, T.; Thompson, P.E.; Nation, R.L.; Li, J. Structure-Activity Relationships of Polymyxin Antibiotics. J. Med. Chem. 2010, 53, 1898–1916. [CrossRef] [PubMed]
25. Duwe, A.K.; Rupar, C.A.; Horsman, G.B.; Vas, S.I. In vitro Cytotoxicity and Antibiotic-Activity of Polymyxin-B Nonapeptide. Antimicrob. Agents Chemother. 1986, 30, 340–341. [CrossRef] [PubMed]
26. Quale, J.; Shah, N.; Kelly, P.; Babu, E.; Backer, M.; Rosas-Garcia, G.; Salamera, J.; George, A.; Bratu, S.; Landman, D. Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-Negative Pathogens in New York City. Microb. Drug Resist. 2012, 18, 132–136. [CrossRef] [PubMed]
27. Magee, T.V.; Brown, M.F.; Starr, J.T.; Ackley, D.C.; Abramite, J.A.; Aubrecht, J.A.; Butler, J.L.; Crandon, F.; Dib-Hajj, M.E.; Flanagan, K.; et al. Discovery of Dap-3 Polymyxin Analogues for the Treatment of Multidrug-Resistant Gram-Negative Nosocomial Infections. J. Med. Chem. 2013, 56, 5079–5093. [CrossRef] [PubMed]
28. Brown, B.; Boakes, S.; Duperchy, E.; Simonovic, M.; Abdulle, O.; Divall, N.; Stanway, S.J.; Wilson, A.; Moss, S.F.; Dawson, M.J. Synthesis and Structure-Activity Relationships of Polymyxin Nonapeptide Derivatives with N-terminal Aminoacyl Moieties. In Proceedings of the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 17–21 September 2015.
29. Gordeev, M.F.; Liu, J.; Wang, X.; Yuan, Z. Antimicrobial Polymyxins for Treatment of Bacterial Infections. WO Patent 2016/100578, 23 June 2016.
30. Rabanal, F.; Grau-Campistany, A.; Vila-Farres, X.; Gonzalez-Linares, J.; Borras, M.; Vila, J.; Manresa, A.; Cajal, Y. A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity. Sci. Rep. 2015, 5, 10558. [CrossRef]
31. Vaara, M.; Vaara, T.; Tyrrell, J.M. Structure-activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity. Peptides 2017, 91, 8–12. [CrossRef]
32. Sato, Y.; Shindo, M.; Sakura, N.; Uchida, Y.; Kato, I. Novel Des-Fatty Acyl-Polymyxin B Derivatives with Pseudomonas aeruginosa-Specific Antimicrobial Activity. Chem. Pharm. Bull. 2011, 59, 597–602. [CrossRef]
33. Sakura, N.; Itoh, T.; Uchida, Y.; Ohki, K.; Okimura, K.; Chiba, K.; Sato, Y.; Sawanishi, H. The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity. Bull. Chem. Soc. Jpn. 2004, 77, 1915–1924. [CrossRef]
34. Tsubery, H.; Ofek, I.; Cohen, S.; Fridkin, M. Structure-function studies of polymyxin B nonapeptide: Implications to sensitization of gram-negative bacteria. J. Med. Chem. 2000, 43, 3085–3092. [CrossRef] [PubMed]
35. Corbett, D.; Wise, A.; Langley, T.; Skinner, K.; Trimby, E.; Birchall, S.; Dorali, A.; Sandiford, S.; Williams, J.; Warn, P.; et al. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob. Agents Chemother. 2017, 61. [CrossRef] [PubMed]
36. Gallardo-Godoy, A.; Muldoon, C.; Becker, B.; Elliott, A.G.; Lash, L.H.; Huang, J.X.; Butler, M.S.; Pelingon, R.; Kavanagh, A.M.; Ramu, S.; et al. Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B. J. Med. Chem. 2016, 59, 1068–1077. [CrossRef] [PubMed]
37. O’Dowd, H.; Kim, B.; Margolis, P.; Wang, W.; Wu, C.; Lopez, S.L.; Blais, J. Preparation of tetra-Boc-protected polymyxin B nonapeptide. Tetrahedron Lett. 2007, 48, 2003–2005. [CrossRef]
38. Vaara, M.; Fox, J.; Loidl, G.; Siikanen, O.; Apajalahti, J.; Hansen, F.; Frimodt-Moller, N.; Nagai, J.; Takano, M.; Vaara, T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 2008, 52, 3229–3236. [CrossRef] [PubMed]
39. Leese, R.A. Antibiotic Compositions for the Treatment of Gram Negative Infections. U.S. Patent 8343912B2, 1 January 2013.
40. Velkov, T.; Roberts, K.D.; Nation, R.L.; Wang, J.P.; Thompson, P.E.; Li, J. Teaching ‘Old’ Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative ‘Superbugs’. ACS Chem. Biol. 2014, 9, 1172–1177. [CrossRef] [PubMed]
41. Ramesh, S.; Govender, T.; Kruger, H.G.; Albericio, F.; de la Torre, B.G. An improved and efficient strategy for the total synthesis of a colistin-like peptide. Tetrahedron Lett. 2016, 57, 1885–1888. [CrossRef]
42. Xu, W.L.; Cui, A.L.; Hu, X.X.; You, X.F.; Li, Z.R.; Zheng, J.S. A new strategy for total solid-phase synthesis of polymyxins. Tetrahedron Lett. 2015, 56, 4796–4799. [CrossRef]
43. Huang, J.X.; Blaskovich, M.A.; Cooper, M.A. Cell- and biomarker-based assays for predicting nephrotoxicity. Expert Opin. Drug Met. 2014, 10, 1621–1635. [CrossRef]
44. Huang, J.X.; Kaeslin, G.; Ranall, M.V.; Blaskovich, M.A.; Becker, B.; Butler, M.S.; Little, M.H.; Lash, L.H.; Cooper, M.A. Evaluation of biomarkers for in vitro prediction of drug induced nephrotoxicity: Comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells. Pharmacol. Res. Perspect. 2015, 3. [CrossRef]
45. Becker, B.; Butler, M.S.; Hansford, K.A.; Gallardo-Godoy, A.; Elliott, A.G.; Huang, J.X.; Edwards, D.J.; Blaskovich, M.A.T.; Cooper, M.A. Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria. Bioorg. Med. Chem. Lett. 2017, 27, 2407–2409. [CrossRef] [PubMed]